By Sherri Oslick --
About
Court Report: Each week we will report briefly on recently filed
biotech and pharma cases, and a few interesting cases will be selected
for periodic monitoring.
Sanofi-Aventis U S LLC et al. v. Sun Pharmaceutical Industries, Limited et al.
2:07-cv-13107; filed July 24, 2007 in the Eastern District of Michigan
Sanofi-Aventis U S LLC et al. v. Sun Pharmaceutical Industries, Limited et al.
3:07-cv-03411; filed July 23, 2007 in the District Court of New Jersey
Sanofi-Aventis U.S. LLC et al. v. Mayne Pharma Ltd. et al.
3:07-cv-03409; filed July 23, 2007 in the District Court of New Jersey
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 5,338,874 ("Cis oxalato (trans 1-1,2-cyclohexanediamine) PT(II) Having Optically High Purity," issued August 16, 1994) following a paragraph IV certification as part of defendants' filing of an ANDA to manufacture a generic version of plaintiffs' Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the Michigan Sun complaint here.
Teva Pharmaceuticals Industries, Ltd., et al. v. Zambon, S.A., et al.
3:07-cv-03438; filed July 23, 2007 in the District Court of New Jersey
Declaratory judgment of infringement of U.S. Patent Nos. 6,699,997 ("Carvedilol," issued March 2, 2004), 6,710,184 ("Crystalline Solids of Carvedilol and Processes for Their Preparation," issued March 23, 2004), 7,056,942 ("Carvedilol," issued June 6, 2006), and 7,126,008 (same title, issued October 24, 2006) based on defendants' filing of a DMF (drug master file) with the FDA for the manufacture of carvedilol (the active ingredient in GSK's Coreg®, used to treat congestive heart failure). View the complaint here.
Cancer Research Technology Ltd. et al. v. Barr Laboratories Inc. et al.
1:07-cv-00457; filed July 20, 2007 in the District Court of Delaware
Infringement of U.S. Patent No. 5,260,291 ("Tetrazine Derivatives," issued November 9, 1993) following a paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of plaintiffs' Temodar® (temozolomide, used to treat brain tumors). View the complaint here.
Sepracor Inc. et al. v. Glenmark Pharmaceuticals, Ltd. et al.
2:07-cv-03385; filed July 20, 2007 in the District Court of New Jersey
Infringement of U.S. Patent Nos. 7,214,683 ("Compositions of Descarboethoxyloratadine," issued May 8, 2007) and 7,214,684 ("Methods for the Treatment of Allergic Rhinitis," issued May 8, 2007) following a paragraph IV certification as part of Glenmark's filing of an ANDA to manufacture a generic version of Sepracor's Clarinex® (desloratidine, used to treat allergies). View the complaint here.
Infosint S.A. v. Forest Pharmaceuticals, Inc.
1:07-cv-06525; filed July 19, 2007 in the Southern District of New York
Infringement of U.S. Patent Nos. 6,458,973 ("Process for the Preparation of 5-Carboxyphthalide," issued October 1, 2002) and 6,703,516 (same title, issued March 9, 2004) based on Forest's sale of Celexa® (citalopram hydrobromide, used to treat depression) and Lexapro® (escitalopram oxalate, used to treat depression and generalized anxiety disorder), manufactured in accordance with the claimed methods. View the complaint here.
Mayne Pharma Ltd. v. Sanofi-Aventis U.S. LLC
3:07-cv-00424; filed July 18, 2007 in the Eastern District of Virginia
Declaratory judgment of non-infringement and invalidity of U.S. Patent No. 6,306,902 ("Oxaliplatin Formulations," issued October 23, 2001) in conjunction with Mayne's filing of an ANDA to manufacture a generic version of Eloxatin® (oxaliplatin for injection, used to treat colorectal cancer). View the complaint here.
Comments